The aim of this paper is to describe a multicenter real-life study about dupilumab in the management of uncontrolled severe CRSwNP with a special focus on blood parameters, including eosinophils, neutrophils, lymphocytes, basophils, IgE, IgG, and IgA. This evidence concerns the gene CD79A and chronic rhinosinusitis with nasal polyps.